Candel Therapeutics (CADL) Interest Coverage Ratio (2022 - 2025)
Candel Therapeutics recorded quarterly Interest Coverage Ratio of 11.12 in Q4 2025, up 86.44% quarter-over-quarter from 82.03 in Q3 2025, and up 46.71% year-over-year from 7.58 in Q4 2024.
Candel Therapeutics' Interest Coverage Ratio history runs 4 years deep, the most recent figure standing at 11.12 for Q4 2025.
- In Q4 2025, Interest Coverage Ratio rose 46.71% year-over-year to 11.12; the TTM figure through Dec 2025 stood at 22.78 (down 42.66% YoY), while the FY2025 annual figure was 22.78, down 42.66% from the prior year.
- Interest Coverage Ratio came in at 11.12 for Q4 2025 at Candel Therapeutics, up from 82.03 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 11.12 in Q4 2025 to a low of 82.03 in Q3 2025.
- A 4-year average of 22.92 and a median of 15.82 in 2023 frame the typical range for Interest Coverage Ratio.
- On a YoY basis, Interest Coverage Ratio climbed as much as 46.71% in 2025 and fell as far as 356.2% in 2025.
- Candel Therapeutics' Interest Coverage Ratio stood at 14.02 in 2022, then slipped by 9.39% to 15.33 in 2023, then tumbled by 36.15% to 20.87 in 2024, then jumped by 46.71% to 11.12 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 11.12, 82.03, and 47.36 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -11.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.12 |
| Sep 30, 2025 | -82.03 |
| Jun 30, 2025 | -47.36 |
| Mar 31, 2025 | -26.57 |
| Dec 31, 2024 | -20.87 |
| Sep 30, 2024 | -17.98 |
| Jun 30, 2024 | -15.12 |
| Mar 31, 2024 | -12.23 |
| Dec 31, 2023 | -15.33 |
| Sep 30, 2023 | -13.25 |
| Jun 30, 2023 | -14.87 |
| Mar 31, 2023 | -15.82 |
| Dec 31, 2022 | -14.02 |
| Sep 30, 2022 | -17.11 |
| Jun 30, 2022 | -20.12 |